The 2023 update of the European Society of Cardiology (ESC) guidelines for the management of cardiovascular disease (CVD) in patients with diabetes was presented in a symposium session at the ESC Congress 2023, held in Amsterdam, the Netherlands, from the 25th–28th of August. The updates redefined the 2019 guidelines, acknowledging recent findings from cardiovascular outcome trials (CVOT) on the safety and efficacy of glucose-lowering medications to provide practice-changing recommendations. The session also introduced a novel tool in predicting CVD risk, SCORE2-Diabetes, an innovative model that accounts for conventional and diabetes-related risk factors, stratified by geographical location.
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً